Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 47 for “"Ras pathway"”.
-
Targeted RAS pathway inhibitors and their rational combinations can sensitise resistant cancer cells to apoptosis
Παρόλο που τα φάρμακα Vemurafenib, Dabrafenib και Encorafenib, - εγκεκριμένοι από το FDA αναστολείς της BRAFV600E μεταλλαγμένης κινάσης-ογκοπρωτεΐνης-, είναι αποτελεσματικά στη θεραπεία του BRAF μεταλλαγμένου μελανώματος, οι νεοπλασίες παχέος εντέρου με BRAF μετάλλαξη παρουσιάζουν ανθεκτικότητα …
-
Immunomodulatory impact of PTPN11/SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer
… (PTPN11/SHP2) is a critical upstream mediator of RAS-MAPK signaling and a central node in adaptive resistance mechanisms evolving with RAS and MEK/ERK inhibition. Accordingly, clinical trials are currently evaluating allosteric SHP2 inhibitors in vertical RAS pathway combination therapies for …
-
TARGETING FARNESYLATION AS A NOVEL THERAPEUTIC APPROACH IN HRAS-MUTANT RHABDOMYOSARCOMA
Activating RAS mutations are found in a subset of fusion-negative rhabdomyosarcoma (FN-RMS), and therapeutic strategies to directly target RAS in these tumors have been investigated, without clinical success to date. A potential strategy to inhibit oncogenic RAS activity is the disruption of RAS …
-
Genetic Analysis of Triple-Negative Breast Cancer and Pineoblastoma
… transposon insertions in genes involved in the Ras pathway (Hras1 and Sos2) or cell motility/migration (Rock2, Fam19a5, and Ntn1). In accordance, bioinformatic analysis revealed that the Ras pathway is enriched in TNBC samples and cell lines. Inhibition of ERK1/2 via ulixertinib suppressed …
-
A Role for RAS in V-CRK Transformation
… and EGF receptor (EGFR) stimulation, signalling pathways that might be activated in v-Crk transformed cells were investigated by analogy to pathways utilized by v-Src and the activated EGFR, and a search for serine/threonine kinases activated in v-Crk transformed CEF was conducted. Mapk was …
-
Investigating drug resistance in RAS-driven models of colon cancer
… number of these deaths are due to KRAS-mutant CRCs, which account for ~40% of all CRC cases and are notoriously resistant to most therapies. Despite showing great promise in preclinical studies, targeted therapies have performed sub-optimally in clinical trials for KRAS mutant …
-
The interaction between the type 1 receptor tyrosine kinases and the oestrogen receptor in human breast cancer: the role of the Ras/Raf-1/MAPK pathway
… regulating the development of resistance. The Ras/Raf-l/MAPK pathway regulates multiple cellular processes such as proliferation, apoptosis, differentiation, senescence and migration. MAPK activation results in phosphorylation of more than 50 substrates within the cytosol and nucleus. One key …
-
Probing positive selection in the human male germline
… advantage by hijacking critical signalling pathways involved in SSC regulation. Over time, through a process termed selfish spermatogonial selection, mutant SSCs clonally expand along the seminiferous tubules in which they originate, resulting in elevated mutation levels. <br><br>To date, …
-
Characterization of the primitive neuroectodermal tumor genome using transposon-mediated insertional mutagenesis.
… efforts have demonstrated specific molecular pathways drive a minority of medulloblastoma and supratentorial PNET but the genetic basis of the majority of these tumors remains poorly understood and anecdotal. To better define the genetic causes of medulloblastoma and supratentorial PNET, we …
-
Prevention of relapse of juvenile myelomonocytic leukemia (JMML) by inhibition of immune checkpoint CD47
… childhood myeloid malignancy driven by RAS pathway mutations, marked by clonal expansion and tissue infiltration of myeloid cells, including macrophages. This study investigated the role of macrophage polarization, phagocytic function, and CD47-mediated immune evasion in JMML …
-
Extracellular Signal-Regulated Kinase as an Integrative Synapse-to-Nucleus Signal
… glutamate receptors, and the classical Ras pathway. I also found that the spatial pattern of synaptic stimulation matters: spatially dispersed stimulation over multiple dendritic branches activated nuclear ERK much more efficiently than clustered stimulation within a single dendritic …
-
Identification of novel therapeutic approaches in juvenile myelomonocytic leukemia (JMML)
… is a rare childhood myeloid neoplasm driven by RAS pathway mutations and characterized by aberrant monocytic and granulocytic proliferation. Allogeneic hematopoietic stem cell transplantation (HSCT) is the standard curative therapy, but relapse is frequent, particularly in patients with PTPN11 …
-
Diabetes-associated metabolic stress on the regulation of endothelial nitric oxide synthase content and mitochondrial function
… of advanced glycation end products (RAGE) and H-Ras pathway are implicated in the upstream signalling events in the downregulation of eNOS in EC. In addition, ER stress, impaired mitochondrial function due to significant reduction of complex-specific oxygen consumption and bioenergetics were …
-
Ras1-mediated Morphogenesis in the Human Fungal Pathogen Cryptococcus Neoformans
… fungal cells within the human host. The Ras1 signal transduction cascade is a major regulator of <italic>C. neoformans</italic> yeast and hyphal-phase morphogenesis, thermotolerance, and pathogenesis. Previous work identified the conserved Rho-GTPases Cdc42 and Rac1 as potential …
-
Evaluating the Therapeutic Potential of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Drosophila Alzheimer's Disease Models
… of the mammalian renin angiotensin system (RAS) result in a significant reduction in the incidence and progression of AD by unknown mechanisms. Here, I used a genetic and pharmacological approach to evaluate the beneficial effects of Angiotensin Converting Enzyme-inhibitors (ACE-Is) and …
-
Cooperating Oncogenic Alterations in Aggressive Pten-Deficient Breast Cancer
… cells promoted secondary tumor engraftment, RAS pathway activation and sensitivity to MEK inhibitors. In basal-like breast cancer, 7% showed combined loss of PTEN and miR-145 as well as poor clinical outcomes. Thus, Pten loss can initiate benign or aggressive mammary tumors depending on …
-
Antihypertensive drugs and risk of cancer: a systematic review and meta-analysis of randomised controlled trials
… II by ACE in the renin-angiotensin system (RAS) pathway. In the present study, no significant association between ACEI and risk of cancer incidence or cancer-related death is reported. Factors such as tissue binding capacity, comparator used, clinical settings, age, and study duration do not …
-
Functional Genomic Analysis of Progression Events in Breast Cancer with a Focus on Stat3, Esr1, and Apobec3
… Stat3 loss appears to co-operate with Notch and Ras pathway activation to promote metastatic dissemination. In a mouse model for Invasive Lobular Carcinoma of the breast (ILC), I found that gain-of-function mutations in Esr1 as well as KRas (Y541S and G12D, respectively), accelerate ILC …
-
The Role of the Rho GEF Arhgef2 in RAS Tumorigenesis
… lethality. Over the past 30 years, the RAS genes have been critical in teaching us the mechanisms underlying the molecular progression of cancer. RAS is mutated in 33% of all cancers and is often an early event in its stepwise progression. As a result, the RAS genes are widely accepted …
-
Determination of readthrough susceptibility among different Schwann cell lines carrying nonsense mutations
… as a tumor suppressor by converting active GTP-Ras to inactive GDP-Ras. 20% of NF1 patients carry a genomic nonsense mutation, which generates a premature termination codon (PTC) in the NF1 mRNA, leading to the formation of a truncated neurofibromin protein. Termination at PTCs can be suppressed …
Page 1 of 3